Technological Innovations in Antibody Production

The field of antibody production has witnessed significant technological advancements over the past years, particularly in hybridoma technology, which remains a cornerstone for monoclonal antibody (mAb) production.

Electrofusion Technology in Hybridoma Preparation

Electrofusion technology can be applied as a cell engineering technique for hybridoma preparation. This method offers substantial improvements in efficiency and control over traditional polyethylene glycol-mediated cell fusion. Electrofusion involves electric field intensity, number of pulses, and pulse duration. However, key challenges in adopting electrofusion include selecting appropriate instruments, optimizing electrical parameters, and precisely controlling cell conditions. Despite this, electrofusion represents a promising advancement for enhancing the specificity and yield of monoclonal antibodies.¹

Hybridoma Cell Screening and Expansion

The process of generating monoclonal antibodies through hybridoma technology involves screening hybridoma cells to select those producing the desired antibodies. This is typically achieved using enzyme-linked immunosorbent assay (ELISA) techniques, among others, to identify antibodies with the right specificity. Following screening, hybridomas that produce the desired antibodies are cloned and propagated to obtain stable cell populations for large-scale antibody production. In recent advancements, hybridoma sequencing has played a transformative role, allowing researchers to decode the genetic blueprints of antibodies produced by hybridoma cells. This step not only enhances the precision of antibody selection but also facilitates optimization processes, paving the way for more efficient antibody production. This expansion can be performed either in vitro, using tissue culture techniques, or in vivo, by inoculating hybridoma cells into the abdomen of a mouse. However, the technology is not without limitations, such as long production times, resource-intensive processes, susceptibility to contamination, and challenges in generating short peptides and fragment antigens.

Clinical Significance and Applications

Hybridoma technology's clinical significance is vast, providing monoclonal antibodies for various diagnostic tests, cancer treatments, and research applications. The specificity and reliability of monoclonal antibodies produced via hybridoma technology have made it an indispensable tool in the diagnosis and treatment of numerous diseases. This technology enables the production of antibodies for detecting foreign antigens, identifying different strains of pathogens, and even treating viral diseases such as AIDS. Moreover, monoclonal antibodies are instrumental in radioimmunodetection and radioimmunotherapy of cancer, highlighting their critical role in modern medicine.² Biointron offers hybridoma sequencing services for antibody discovery and production.

References: 

1. Kou, J., Shen, J., Wang, Z., & Yu, W. (2023). Advances in hybridoma preparation using electrofusion technology. Biotechnology Journal, 18(10), 2200428. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/biot.202200428

2. Mitra, S., & Tomar, P. C. (2021). Hybridoma technology; advancements, clinical significance, and future aspects. Journal of Genetic Engineering and Biotechnology, 19(1), 1-12. https://doi.org/10.1186/s43141-021-00264-6https://www.sciencedirect.com/science/article/pii/S1687157X23006236